Comparing Senolytic Treatments in Mice with Tau Protein Accumulation
Author Information
Author(s): Orr Miranda, Garbarino Valentina, Orr Timothy
Primary Institution: Wake Forest University School of Medicine
Hypothesis
Does fisetin provide similar or better senolytic effects compared to dasatinib plus quercetin in tau transgenic mice?
Conclusion
Both senolytic treatments were equally protective against neurodegeneration, but dasatinib plus quercetin had a greater effect on tau neuropathology.
Supporting Evidence
- Both senolytic treatments reduced brain pathology in tau transgenic mice.
- D+Q showed a greater effect on tau neuropathology compared to vehicle treatment.
- Treatment-specific effects were observed with genotype interactions.
Takeaway
Researchers tested two treatments to help mice with brain problems caused by tau protein. Both treatments worked well, but one was better at fixing brain damage.
Methodology
Fourteen-month-old male and female wild type and tau transgenic mice were treated with either dasatinib plus quercetin, fisetin, or a vehicle for 12 weeks, with various physical and behavioral outcomes measured.
Participant Demographics
Fourteen-month-old male and female wild type and tau transgenic mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website